Publications by authors named "Paul Newbold"

Claim this Profile
I
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.
David Strawn, James G Krueger, Robert Bissonnette, Kilian Eyerich, Laura K Ferris, Paul Newbold

JCI Insight· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness.
Xingnan Li, Paul Newbold, Rohit Katial, Ian Hirsch, Huashi Li

J Allergy Clin Immunol Pract· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial.
Gail M Gauvreau, Roma Sehmi, J Mark FitzGerald, Richard Leigh, Donald W Cockcroft, Paul Newbold

Eur Respir J· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAL Fluid Eosinophilia Associates With Chronic Lung Allograft Dysfunction Risk: A Multicenter Study.
Jamie L Todd, Jeremy M Weber, Francine L Kelly, Megan L Neely, Hillary Mulder, Paul Newbold

Chest· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma.
Eugene R Bleecker, Deborah A Meyers, Dean Billheimer, Huashi Li, Paul Newbold

J Allergy Clin Immunol Pract· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
Rania Dagher, Varsha Kumar, Alan M Copenhaver, Sandra Gallagher, Mahboobe Ghaedi, Paul Newbold

Eur Respir J· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN).
Bert Rutten, Simon Young, Sarah Aldridge, Rick Davies, Mark Fidock, Paul Newbold

J Immunol Methods· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker.
Bert Rutten, Simon Young, Magdalena Rhedin, Marita Olsson, Nisha Kurian, Paul Newbold

PLoS One· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease.
Andrew Higham, Augusta Beech, Sophie Wolosianka, Natalie Jackson, Gabriella Long, Paul Newbold

Allergy· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between airway immunoglobulin activity and eosinophils in COPD.
Thomas Southworth, Andrew Higham, Umme Kolsum, Jian Li, Thomas Scott, Paul Newbold

J Cell Mol Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue.
Prajakta Jogdand, Premkumar Siddhuraj, Michiko Mori, Caroline Sanden, Jimmie Jönsson, Paul Newbold

Eur Respir J· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus-predominant subgroup.
Sarah Diver, Matt Richardson, Koirobi Haldar, Michael A Ghebre, Mohammadali Y Ramsheh, Paul Newbold

Allergy· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
Gerard J Criner, Bartolome R Celli, Dave Singh, Alvar Agusti, Alberto Papi, Paul Newbold

Lancet Respir Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
David J Jackson, Marc Humbert, Ian Hirsch, Paul Newbold, Esther Garcia Gil

Adv Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sputum is reduced in COPD following treatment with benralizumab.
Leena George, Adam Wright, Vijay Mistry, Amanda Sutcliffe, Latifa Chachi, Paul Newbold

Int J Chron Obstruct Pulmon Dis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma.
Latifa Chachi, Sarah Diver, Himanshu Kaul, Marlon C Rebelatto, Anmarie Boutrin, Paul Newbold

Eur Respir J· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benralizumab for the Prevention of COPD Exacerbations.
Gerard J Criner, Bartolome R Celli, Christopher E Brightling, Alvar Agusti, Alberto Papi, Paul Newbold

N Engl J Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benralizumab for -Negative Hypereosinophilic Syndrome.
Fei Li Kuang, Fanny Legrand, Michelle Makiya, JeanAnne Ware, Lauren Wetzler, Paul Newbold

N Engl J Med· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
Sriram Sridhar, Hao Liu, Tuyet-Hang Pham, Gautam Damera, Paul Newbold

Respir Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Periostin and Dipeptidyl Peptidase-4: Potential Biomarkers of Interleukin 13 Pathway Activation in Asthma and Allergy.
Claire Emson, Tuyet-Hang Pham, Scott Manetz, Paul Newbold

Immunol Allergy Clin North Am· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
Eugene R Bleecker, Michael E Wechsler, J Mark FitzGerald, Andrew Menzies-Gow, Yanping Wu, Paul Newbold

Eur Respir J· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
Lawrence DuBuske, Paul Newbold, Yanping Wu, Frank Trudo

Allergy Asthma Proc· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles.
Michael A Ghebre, Pee Hwee Pang, Sarah Diver, Dhananjay Desai, Mona Bafadhel, Paul Newbold

J Allergy Clin Immunol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Bradley E Chipps, Paul Newbold, Ian Hirsch, Frank Trudo, Mitchell Goldman

Ann Allergy Asthma Immunol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma.
Roma Sehmi, Hui Fang Lim, Manali Mukherjee, Chynna Huang, Katherine Radford, Paul Newbold

J Allergy Clin Immunol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis